-
Study aim
-
The evaluation of Melatonin effect on short outcome in newborns with hypoxic ischemic encephalopathy
-
Design
-
This is a clinical trial, phase II, in which 66 eligible patients will be assigned to the intervention and control groups
-
Settings and conduct
-
The eligible newborns with hypoxic- ischemic- encephalopathy referring to the Fatemieh Hospital in Hamadan city during the study period will be enrolled .
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: At least one of the diagnostic criteria of HIE include: APGAR score <5 at 5 minutes, Fetal heart rate <60 bpm, Prolonged metabolic acidosis(>1 hour), Need of positive pressure ventilation>1 min or delay in crying >10 min of birth, Occurrence of acute perinatal events, Seizures occur in the first 24 to 48 hours after birth.
Exclusion criteria: Gestational age <36weeks, Congenital anomalies, Unperforated anus, Intracranial hemorrhage
-
Intervention groups
-
Intervention group: Routine treatment plus intravenous injection of melatonin 1O mg/kg day on the first, second and third days and then every other day on the fifth, seventh, and ninth days to a maximum of 6 doses, Control group: Just routine treatment
-
Main outcome variables
-
Primary outcome: Seizure attacks, time of onset of consciousness, the occurrence of death, duration of hospitalization, time to start oral nutrition Secondary outcome: Drug complications such as thrombocytopenia.